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Regulation of inositol phosphate synthesis was examined in a primary culture of vascular smooth muscle 
cells grown on collagen-coated microcarriers. In the presence of LiCl (10 mM), four agonists [serotonin, 
angiotensin, (arginine) vasopressin and noradrenaline] were found to stimulate the formation of inositol 
phosphates in a dose-dependent manner. All agonists were found to have identical and additive effects on 
the time course of inositol phosphate formation. Therefore, our primary cell culture technique was proved 
to give smooth muscle cells suitable for the study of modulation of phosphoinositide metabolism in response 
to physiological effecters. 
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1. INTRODUCTION 
The rise of intracellular Ca2+ concentration has 
been shown to play a crucial role in the regulation 
of vascular smooth muscle contraction. It appears 
that the mechanism by which some hormones in- 
duce an increase in intracellular Ca2+ concentra- 
tion involves the breakdown of phosphatidylinosi- 
to1 4,5bisphosphate (PIP2) into inositol 1,4,5-tri- 
sphosphate (IP3) and diacylglycerol [ 11. IPr has 
been shown in several systems to be able to release 
Ca2+ from the endoplasmic reticulum [2,3]. 
Abbreviations: AH, angiotensin II; AVP, (Arg)- 
vasopressin; NA, noradrenaline; 5-HT, S-hydroxytryp- 
tamine; IP, myo-inositol phosphate; IPs, myo-inositol 
1,4,5trisphosphate; PBS, phosphate-buffered saline; 
PIP2, phosphatidylinositol 4,$bisphosphate; d(CH&- 
AVP, [l-,&mercapto-&~‘-cyclopentamethylene-propi- 
onic acid)d-arginine] vasopressin 
In the past few years, vascular smooth muscle 
cells from either primary cultures [4-61 or stable 
cell lines [7-91 have been used to study the 
biochemical coupling between regulatory hormone 
receptors and the main physiological response, i.e. 
contraction [lo-l 31. Smooth muscle cells from rat 
aorta respond to and have receptors for the hor- 
mones such as vasopressin and angiotensin and for 
neurotransmitters such as noradrenaline and 
serotonin. These responses have been shown to be 
mediated by phosphoinositide breakdown in aorta 
[10,14-161 but none of the primary cell cultures 
described so far responded to all 4 agonists. In 
fact, vascular smooth muscle cells seem to lose 
some of their initial properties during the exponen- 
tial phase of proliferation, thereby limiting their 
usefulness in studies on vasoactive hormone action 
[17-191. 
We show here that aortic smooth muscle cells 
cultured on collagen-coated microcarriers retain 
their ability to respond to the 4 agonists by an in- 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/$3.50 0 1986 Federation of European Biochemical Societies 27 
Volume ZOO, number 1 FEBS LETTERS 
crease in inositol phosphate formation. Some 
properties of these stimulations are also discussed. 
3. RESULTS AND DISCUSSION 
2. MATERIALS AND METHODS 
2.1. Materials 
Hormones ((Arg) AVP, AII, NA, S-HT) were 
from Sigma (St. Louis, MO). ~yo-2-[3H]Inositol 
(16.5 Cilmmol) was obtained from New England 
Nuclear. Culture medium and supplements were 
purchased from Biomerieux and fetal calf serum 
from Gibco. Collagen-coated microcarriers were 
from IBF (Societe Chimique Pointet Girard). All 
other chemicals were of analytical grade. 
2.2. Preparation of aortic myocytes 
Vascular smooth muscle cells were prepared 
from male adult rat aortas as in [6] with some 
modifications. Briefly, male Wistar rats (12 weeks 
old) were killed by cervical dislocation. Aortas 
were dissected and digested for 30 min in a col- 
lagenase solution (type II, 300 U/ml). Adventitia 
and intima were removed and the release of free 
vascular smooth muscle cells was achieved through 
incubation of the remaining media for 90 min in a 
collagenase-elastase olution. Myocytes were then 
cultured with continuous stirring for 13-14 days 
on collagen-coated microcarriers in modified 
Eagles medium (MEM) supplemented with 10m5 M 
L-proline, 1.5 x 10e6 M ascorbic acid and 5% 
fetal calf serum. 
As shown in fig. 1, the 4 main regulatory agents 
of rat aortic contraction were able to stimulate IP 
accumulation when tested for 45 min in the 
presence of LiCl. Hormone concentrations were 
10m4 M for 5-HT, lo-’ M for AI1 and AVP, 
lo-’ M for NA and accumulation of IP was 
stimulated 5.63 f 0.76,5.28 f OS, 2.94 f 0.35 and 
1.78 + O-3-fold, respectively (mean + SE of 4 ex- 
periments). The effect of noradrenaline (NA) is 
likely to be mediated by an ai-adrenergic effect 
since a similar effect was observed in the presence 
of lo-’ M phenylephrine, moreover there was no 
detectable stimulation of the synthesis of IP by 
lo-’ M clonidine, a specific cuz-agonist. All 
responses were abolished in the presence of the 
specific antagonist of each hormone (fig.2). 
Dose-response curves are presented in fig.3. 
Half-maximal activations were obtained in the 
presence of 5.3 x 10m6 M 5-HT, 3.5 x low9 M AII, 
2.3. Measurement of phosphoinositide hydrolysis 
In intact cells, labeling of phosphoinositides was 
performed by incubation for 2 days in the medium 
previously described, complemented with 2.5 pCi/ 
ml myo-[3H]inositol. Labeled cells were washed 3 
times with PBS buffer before use and then sampled 
(approx. 200000 cells per sample). Each sample 
(890~1) was incubated with 10 mM LiCl in PBS 
buffer to inhibit inositol-l-phosphate phosphatase 
and to allow accumulation of inositol phosphates 
[20,21]. Agonists were added and cells incubated at 
37°C for various times. The reaction was stopped 
by addition of 400~1 of 10% perchloric acid, and 
3H-labeled inositol phosphates extracted, resolved 
from other labeled material and quantified as 
described [22]. 
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Fig. 1. Screening or different hormonal stimulation for 
IP accumulation in the presence of 10 mM LiCl. Data 
shown are means, expressed as percentage of the 
maximum response induced by each agonist, of triplicate 
determinations and are representative of 3 such studies. 
C, controi; CLO, clonidine (lo-’ M); Phe, 
phenylephrine (lo-’ M); NA, noradrenaline (lo-’ M); 
CAR, carbachol (10e4 M); His, histamine (10m4 M); 
AVP, (Arg) vasopressin (lo-’ M); AD, angiotensin II 
(lo-’ M); 5-HT, S-hydroxytryptamine (10e4 M); 
ACTH, adrenocorticotropic hormones (4-10) (10e6 M); 
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5HT AU AVP NA 
4.5 x 10T9 M AVP and 2.3 x iO-’ M NA. These 
values are very close to those reported to produce 
an increase in phosphatidylinositol metabolism 
and/or contraction in aorta tissues or cells 
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Fig.2. Antagonism of IP accumulation elicited by the 4 
stimulations. Open bars: responses obtained with 
10m4 M 5-HT, lo-’ M AII, lo-’ M AVP and lo-’ M 
NA. Hatched bars: responses obtained in the presence of 
the following antagonists - ketanserin (10e5 M), for 
S-HT stimulation; (Sar, Be) Ang (10e6 M), for AI1 
stimulation; d(CH&AVP (4 x IO-’ M), for AVP 
stimulation; prazosin (10m6 M), for NA stimulation. 
Antagonists were applied 10 min prior to addition of the 
agonists. Results are means + SE of a determination 
performed in triplicate. 
(10,14-161. The time course of accumulation of 
the 3 inositol phosphates was measured in the 
presence of concentrations of agonists able to give 
maximal activation of IP formation. Fig.4 shows 
that all agonists exhibit very similar behaviour with 
respect to their kinetics. 
The results presented in fig.5 indicate that 
phosphatidylinositol-bisphosphate phosphodies- 
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Fig.3. Dose-response curves to (AH, (Arg)-AVP, 5-HT, NA) for accumulation of IP. Data shown are the means, 
expressed as a percentage of the maximum response induced by each agonist, of triplicate determinations and are 
representative of 3 such studies. 
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Fig.4. Time course of the effect of the different agonists 
on IP accumulation i  the presence of 10 mM LiCl. 
Each point is the mean of a determination performed in 
triplicate and representative of 3 such studies. (0) 
1O-4 M S-HT, (m) lo-’ M AII, (0) lo-’ M AVP, (0) 
1O-5 M NA. 
Fig.5. Additivity of the different agonists in the presence 
of 10 mM LiCl. Concentrations of agonists: 5-HT, 
10e4 M; AII, lo-’ M; AVP, lo-’ M. Each bar indicates 
a mean f SE of 3 determinations. 
terase is not maximally activated, irrespective of 
the hormone used for stimulation. This figure 
shows an additivity of the respective hormonal 
stimulations, each hormone being used at a con- 
centration giving a maximal independent stimula- 
tion. These results indicate that part of but not all 
phosphodiesterase activity might be activated 
through single hormone stimulation. Therefore, it 
seems that the rate of IP3 formation is limited only 
by the number of phosphodiesterase molecules 
activated upon hormone binding. The additivity 
tests were made at 45 min when the rate of IP3 
accumulation was still in the steady-state phase 
(fig.4). It is possible, however, that in the presence 
of 2 or 3 hormones, steady-state conditions no 
longer exist, thereby explaining the close but not 
accurate additivity of hormonal stimulations. 
Another explanation could be the presence in the 
culture of different types of myocytes which could 
express the 4 receptors differently. 
Our preliminary experiments indicate that 
vascular smooth muscle cells prepared as described 
above and grown on collagen-coated microcarriers 
still present responsiveness to hormones and 
properties of vascular material. All 4 receptors 
tested were functional and their activation upon 
binding of the respective hormones led to activa- 
tion of IP formation, probably through activation 
of the PIP2 phosphodiesterase. Culture on 
microbeads allowed us to obtain large amounts of 
material suitable for biochemicals as well as phar- 
macological studies. The first studies reported 
herein indicate that these cells are very similar to in 
situ cells. The precise characterization of each 
receptor and the analyses of their similarities with 
intact artery, in terms of hormone binding, poten- 
cy in the triggering of muscle contraction will be 
further investigated. 
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